Creating tumor models to test new cancer treatments
Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.
This study is trying to see how well new cancer treatments work on tumor samples from patients with specific mutations.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Antoine Lacassagne Academic / other |
| Drugs / interventions | Abciximab |
| Locations | 1 site (Nice) |
| Trial ID | NCT06782451 on ClinicalTrials.gov |
What this trial studies
This study collects tumor samples from patients with specific mutations to develop spheroid cell cultures. These spheroids will be used to model how tumors respond to various anticancer therapies. By testing different therapeutic molecules on these spheroids, researchers aim to evaluate the effectiveness of new and existing treatments tailored to the patient's tumor characteristics. Tumor samples will be obtained through routine biopsies or surgeries.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a malignant tumor at an advanced stage and a mutation of interest identified.
Not a fit: Patients with multiple primary malignant tumors or those with certain viral infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective cancer treatments for patients with specific tumor mutations.
How similar studies have performed: Other studies have shown promise in using tumor-derived models to test cancer therapies, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older. * Patient for whom at least one mutation deemed of interest by the investigator has been identified. * Patient with a malignant tumor at a locally advanced or metastatic stage, for whom a tissue tumor sample (via surgery, radiology, or endoscopy) is scheduled as part of their standard care. * Tumor volume deemed sufficient by the physician to ensure an adequate amount of material for analysis by the pathologist and the transfer of a part of the tumor sample to the Laboratory of Translational Research in Oncology for the study. * INR \< 1.5; Platelets \> 50,000/μL. * Patient who has been informed of the study and has signed the informed consent form. * Patient affiliated with a social security insurance. Exclusion Criteria: * Patient with multiple primary malignant tumors. * Patient with a known HIV, Hepatitis C, or Hepatitis B infection. * Patient on: * Clopidogrel (hydrogensulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) with no possibility of suspension for 5 days, * Low molecular weight heparin with no possibility of dose suspension before the procedure, * Fondaparinux with no possibility of suspension, * Abciximab with no possibility of suspension for 24 hours and aPTT \< 50s and ACT \< 150s, * Eptifibatide or Tirofiban Hydrochloride Monohydrate or Argatroban with no possibility of suspension 4 hours before the procedure, * Bivalirudin with no possibility of suspension 2-3 hours if CrCL \>50 mL/min or 3-5 hours if CrCL \<50 mL/min before the procedure, * Dabigatran etexilate with no possibility of suspension 2-3 days if CrCL \>50 mL/min or 3-5 days if CrCL \<50 mL/min before the procedure. * Patient considered vulnerable; vulnerable persons are defined in articles L1121-5 to L1121-8: * Pregnant women, parturients, and breastfeeding mothers, * Individuals deprived of their liberty by a judicial or administrative decision, individuals hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and individuals admitted to a healthcare or social facility for reasons other than research, * Adults under legal protection or unable to express their consent.
Where this trial is running
Nice
- Centre Antoine Lacassagne — Nice, France (Recruiting)
Study contacts
- Study coordinator: Study coordinator
- Email: DRCI-Promotion@nice.unicancer.fr
- Phone: +33 04 92 03 14 76
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.